Holen Sie sich die Stockscreener-App
30.31
2.95%
-0.92
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Alliancebernstein L.P. Reduces Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Reports Positive Phase 3 Gene Therapy Results - MSN
Ultragenyx Pharmaceutical Inc. $RARE Shares Purchased by Parkman Healthcare Partners LLC - MarketBeat
Ultragenyx Makes Bid for Dimension TherapeuticsBiotech Movers - TheStreet
Ultragenyx Pharmaceutical's (RARE) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Ultragenyx Pharmaceutical Inc. $RARE Shares Bought by Fred Alger Management LLC - MarketBeat
121,510 Shares in Ultragenyx Pharmaceutical Inc. $RARE Purchased by Cubist Systematic Strategies LLC - MarketBeat
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome - Zacks Investment Research
Ultragenyx releases long-term phase 3 data on gene therapy for metabolic disorder - MSN
Alyeska Investment Group L.P. Has $54.15 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Cinctive Capital Management LP Purchases 14,301 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-09-2025 04 - MarketScreener
Ionis Rare Neurological Disease Candidate Receives FDA Breakthrough StatusIonis Pharmaceuticals (NASDAQ:IONS) - Benzinga
RARE Reports Positive Long-Term Data From Metabolic Disorder Study - sharewise.com
Ultragenyx stock maintains Buy rating at H.C. Wainwright on strong GSD1a data By Investing.com - Investing.com South Africa
Ultragenyx stock maintains Buy rating at H.C. Wainwright on strong GSD1a data - Investing.com
Ultragenyx reports positive long-term data for GSDIa gene therapy - Investing.com
Cutter Capital Management LP Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx reports positive long-term data for GSDIa gene therapy By Investing.com - Investing.com Canada
Ultragenyx Pharmaceutical Reports Positive Phase 3 Data on Rare Metabolic Disorder Treatment - MarketScreener
Ultragenyx Pharmaceutical Inc. Reports Positive Phase 3 Results for DTX401 Gene Therapy in Glycogen Storage Disease Type Ia with Significant Reductions in Cornstarch Intake and Improved Glycemic Control - Quiver Quantitative
Ultragenyx Announces Positive Longer-term Data from Phase 3 - GlobeNewswire
Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) - Yahoo Finance
Ultragenyx SVP Huizenga sells $2.6k in shares - Investing.com
Will Ultragenyx Pharmaceutical Inc. Bounce From 52 Week LowJuly 2025 Drop Watch & Safe Capital Growth Stock Tips - beatles.ru
Ultragenyx Pharmaceutical Inc. Volume Confirms Breakout — Analysts Bullish2025 Bull vs Bear & Free AI Powered Buy and Sell Recommendations - beatles.ru
Adage Capital Partners GP L.L.C. Has $77.82 Million Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
5 Companies Caught on a Carousel of FDA Confusion - BioSpace
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 6.5%Time to Buy? - MarketBeat
Real time scanner hits for Ultragenyx Pharmaceutical Inc. explained2025 Top Gainers & Consistent Profit Alerts - Newser
Ultragenyx Pharmaceutical Inc. stock daily chart insightsShort Setup & Daily Risk Controlled Trade Plans - Newser
Vestal Point Capital LP Cuts Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Institutional scanner results for Ultragenyx Pharmaceutical Inc.Market Sentiment Report & Entry Point Confirmation Alerts - Newser
Graham Capital Management L.P. Increases Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
How to use Fibonacci retracement on Ultragenyx Pharmaceutical Inc.Weekly Trend Report & Fast Gain Stock Tips - Newser
Live market analysis of Ultragenyx Pharmaceutical Inc.Portfolio Risk Report & Fast Exit Strategy with Risk Control - Newser
What machine learning models say about Ultragenyx Pharmaceutical Inc.July 2025 Market Mood & Verified Technical Trade Signals - Newser
B. Metzler seel. Sohn & Co. AG Boosts Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
What earnings revisions data tells us about Ultragenyx Pharmaceutical Inc.2025 Institutional Moves & AI Powered Market Trend Analysis - Newser
Is Ultragenyx Pharmaceutical Inc. stock a good pick for beginnersGap Up & Long-Term Growth Plans - خودرو بانک
Ultragenyx Pharmaceutical Inc. recovery potential after sell offWeekly Investment Report & Safe Entry Point Identification - Newser
Applying sector rotation models to Ultragenyx Pharmaceutical Inc.July 2025 Selloffs & Safe Capital Growth Tips - Newser
Real time pattern detection on Ultragenyx Pharmaceutical Inc. stock2025 Investor Takeaways & Risk Managed Trade Strategies - Newser
Rare Disease Therapy Approvals By FDA Speed Up Via New ProcessNeurogene (NASDAQ:NGNE) - Benzinga
Ultragenyx’s Strategic Momentum: A Rare Disease Biotech on the Cusp of Multiple Catalysts - AInvest
Ultragenyx's Strategic Momentum in Rare Disease Innovation and Commercialization - AInvest
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-04-2025 10 - MarketScreener
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
News impact scoring models applied to Ultragenyx Pharmaceutical Inc.Weekly Risk Report & Entry Point Confirmation Signals - Newser
Long term hold vs stop loss in Ultragenyx Pharmaceutical Inc.Global Markets & Low Risk High Reward Trade Ideas - Newser
Driehaus Capital Management LLC Has $30.88 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
What does recent volatility data suggest for Ultragenyx Pharmaceutical Inc.2025 Key Lessons & High Accuracy Investment Signals - Newser
A | Is Ultragenyx Pharmaceutical Inc. stock good for income investorsJuly 2025 Review & Stepwise Trade Signal Guides - خودرو بانک
0.93%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):